Linsitinib
- Generic Name
- Linsitinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23N5O
- CAS Number
- 867160-71-2
- Unique Ingredient Identifier
- 15A52GPT8T
- Background
An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Graves' Disease Pipeline Drug Research Report 2024
The 'Graves' Disease - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides a comprehensive overview of the current pipeline landscape for Graves' Disease treatments, including detailed descriptions of drugs like Batoclimab, VRDN-001, and Linsitinib, which are in various stages of clinical development. The report highlights key companies such as Viridian Therapeutics, Immunovant Sciences, and Sling Therapeutics, and covers therapeutic assessments, pipeline development activities, and emerging trends in drug development for Graves' Disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath